Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.63 |
| ▸ | THPO | P40225 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.48 |
| ▸ | MME | P08473 | 6/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3014643 | 1.00 | ACE (0.74) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL1049889 | 1.00 | ACE (0.74) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL931221 | 0.85 | ACE (1.00) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL6927677 | 0.85 | ACE (0.71) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL930664 | 0.85 | ACE (0.71) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL23835494 | 0.85 | ACE (0.71) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL525145 | 0.85 | ACE (1.00) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL931219 | 0.85 | ACE (1.00) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL928750 | 0.85 | ACE (1.00) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL929422 | 0.85 | ACE (1.00) | ACEKDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4045063-B1 | COMPOSITION AND METHOD FOR TREATMENT OF MULTIPLE SCLEROSIS | WUHAN VAST CONDUCT SCIENCE FOUND CO LTD (CN) | 2024-10-02 | — | — | EP | claimed |
| EP-4072565-B1 | GOLD CLUSTERS (AuCs) AND COMPOSITION FOR TREATMENT OF LIVER CIRRHOSIS | WUHAN VAST CONDUCT SCIENCE FOUND CO LTD (CN) | 2024-08-14 | — | — | EP | claimed |
| US-20240238443-A1 | Application of AuCs or Substances Containing AuCs in the Preparation of Drugs for Preventing and/or Treating Glaucoma | Shenzhen Profound-View Pharma Tech Co., Ltd (CN) | 2024-07-18 | — | — | US | claimed |
| US-11969477-B2 | Application of AuCs or substances containing AuCs in the preparation of drugs for preventing and/or treating glaucoma | Shenzhen Profound-View Pharma Tech Co., Ltd (CN) | 2024-04-30 | — | — | US | claimed |
| US-20240122973-A1 | LIGAND-BOUND ZINC SULFIDE NANOPARTICLES, METHODS FOR MAKING THE SAME, AND THEIR USE FOR TREATMENT | WUHAN VAST CONDUCT SCIENCE FOUNDATION CO., LTD. (CN) | 2024-04-18 | — | — | US | claimed |
| EP-4255449-A1 | LIGAND-BOUND ZINC SULFIDE NANOPARTICLES, METHODS FOR MAKING THE SAME, AND THEIR USE FOR TREATMENT | Wuhan Vast Conduct Science Foundation Co., Ltd. (CN) | 2023-10-11 | — | — | EP | claimed |
| CN-116482280-A | Method for determining aminopiperidine dihydrochloride isomer | 北京北陆益康医药研发有限公司 | 2023-07-25 | — | — | CN | claimed |
| US-20220323608-A1 | Application of AuCs or Substances Containing AuCs in the Preparation of Drugs for Preventing and/or Treating Glaucoma | Shenzhen Profound-View Pharma Tech Co., Ltd (CN) | 2022-10-13 | — | — | US | claimed |
| WO-2022198438-A1 | LIGAND-BOUND ZINC SULFIDE NANOPARTICLES, METHODS FOR MAKING THE SAME, AND THEIR USE FOR TREATMENT | WUHAN VAST CONDUCT SCIENCE FOUNDATION CO., LTD. (CN) | 2022-09-29 | — | — | WO | claimed |
| EP-3449945-B1 | SUBSTANCE CONTAINING GOLD CLUSTER AND PREPARATION METHOD AND USE THEREOF | SHENZHEN PROFOUND VIEW PHARMA TECH CO LTD (CN) | 2022-02-09 | — | — | EP | claimed |
| CN-107261148-A | Methylphenidate prodrug, its preparation and application | 凯姆制药公司 | 2017-10-20 | — | — | CN | claimed |
| EP-2736510-A2 | METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | Kempharm, Inc. (US) | 2014-06-04 | — | — | EP | claimed |
| CN-103826633-A | Methylphenidate prodrugs, methods of making and using the same | KEMPHARM INC | 2014-05-28 | — | — | CN | claimed |
| US-20140080795-A1 | NRF2 Deficiency Influences Susceptibility to Steroid Resistance via HDAC2 Reduction | UNIVERSITY OF ROCHESTER (US) | 2014-03-20 | — | — | US | claimed |
| WO-2013016668-A2 | METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | KEMPHARM INC. (US) | 2013-01-31 | — | — | WO | claimed |
| WO-2012068454-A2 | NRF2 DEFICIENCY INFLUENCES SUSCEPTIBILITY TO STEROID RESISTANCE VIA HDAC2 REDUCTION | UNIVERSITY OF ROCHESTER (US) | 2012-05-24 | — | — | WO | claimed |
| EP-1676113-A4 | DECONTAMINATION AND CONCENTRATION KIT FOR MYCOBACTERIA | SALUBRIS INC (US) | 2006-11-15 | — | — | EP | claimed |
| EP-1676113-A2 | DECONTAMINATION AND CONCENTRATION KIT FOR MYCOBACTERIA | Salubris Inc. (US) | 2006-07-05 | — | — | EP | claimed |
| WO-2005040751-A2 | DECONTAMINATION AND CONCENTRATION KIT FOR MYCOBACTERIA | SALUBRIS INC. (US) | 2005-05-06 | — | — | WO | claimed |
| US-20050089948-A1 | Decontamination and concentration kit for mycobacteria | SALUBRIS, INC. | 2005-04-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240122973-A1 | LIGAND-BOUND ZINC SULFIDE NANOPARTICLES, METHODS FOR MAKING THE SAME, AND THEIR USE FOR TREATMENT | SOD1, APP, PSEN1 | ACE 557/4885KDM4E 4432/4885MAPT 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.